Wake Forest University Health Sciences: Leukemia, Myeloid trials

The registry lists 22 Leukemia, Myeloid studies with Wake Forest University Health Sciences as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 9Phase 3 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Leukemia Stem Cell Detection in Acute Myeloid LeukemiaTerminatedNCT02927938Phase 3Results posted
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedNCT02484391Phase 1Results posted
• Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02337478Phase 2Results posted
• Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute LeukemiaCompletedNCT01869777Not applicableResults posted
• A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic LeukemiaCompletedNCT01656031Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 2Results posted
• CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)WithdrawnNCT05854966Phase 2
• Preparatory Work to Assess Adherence to Oral ChemotherapyCompletedNCT02895542
• Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)CompletedNCT02662933Not applicable
• Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)CompletedNCT02662920
• Metabolic Changes in Blood Samples From Patients With Acute Myeloid LeukemiaCompletedNCT02581917
• 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaWithdrawnNCT02472626Phase 1/2
• LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous LeukemiaCompletedNCT01999556
• Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaApproved for marketingNCT01869803
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01768897Phase 1
• Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
• Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyCompletedNCT01519596Not applicable
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial TreatmentCompletedNCT00072579Phase 2
• DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00003840Phase 1/2